10-Q: Cooper Companies Reports Strong Q1 2026 Earnings Growth

The Cooper Companies, Inc. reported a significant increase in net income and diluted EPS for the first quarter of fiscal 2026, driven by strong performance across both CooperVision and CooperSurgical segments.

Summary

• Net sales increased by 6.16% to $1,024.1 million for the three months ended January 31, 2026, compared to $964.7 million in the prior year.
• Net income rose by 25.4% to $130.8 million, up from $104.3 million in the same period last year.
• Diluted earnings per share (EPS) increased by 26.9% to $0.66, compared to $0.52 in the prior year.
• Operating income grew by 16.9% to $212.8 million.
• Cash provided by operating activities increased by 36.9% to $260.9 million.
• The company repurchased 1.1 million shares of common stock for $92.5 million during the quarter.
• A legal dispute with HMRC regarding payroll tax from the 2014 Sauflon acquisition resulted in an unfavorable FTT decision, which the company intends to appeal, with a potential loss ranging from $0 to $71.7 million plus interest.
• Debt maturity for $950.0 million of term loans was extended to February 3, 2031, post-quarter end.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong quarter with significant growth in key financial metrics and effective debt management, despite an unfavorable legal ruling that the company intends to appeal.

Positives

• Strong net sales growth of 6.16% overall, with CooperVision up 7.59% and CooperSurgical up 3.26%.
• Significant increase in net income by 25.4% and diluted EPS by 26.9%.
• Operating income saw a healthy increase of 16.9%.
• Cash flow from operating activities improved substantially by 36.9% to $260.9 million.
• Interest expense decreased by 13.8% due to lower average debt balances.
• Successful extension of $950.0 million in term loan maturity to February 2031, improving the debt profile.
• Continued share repurchase program, with $92.5 million spent in the quarter and $873.9 million remaining authorized.
• CooperVision's Toric and multifocal category grew 10%, driven by MyDay and Biofinity.
• CooperSurgical's Fertility net sales increased by 6% due to consumable products.

Negatives

• Gross margin remained flat at 68%.
• Corporate operating loss increased by 10% due to higher share-based compensation expenses.
• Working capital decreased from $993.6 million to $538.1 million, primarily due to an increase in short-term debt.
• An unfavorable decision from the U.K. First-tier Tribunal regarding a payroll tax dispute, with a potential loss of up to $71.7 million plus interest, although the company intends to appeal.
• Asia Pacific net sales for CooperVision decreased by 4%.
• Office and surgical net sales for CooperSurgical only increased by 2%, partially offset by a decrease in Paragard contraceptive IUD revenue.

Risks

• Adverse changes in global or regional general business, political, and economic conditions, including international conflicts (e.g., Middle East), natural disasters, and pandemic conditions.
• Impact of tariffs, customs duties, and other trade protection measures.
• Foreign currency exchange rate and interest rate fluctuations, which could decrease net sales and earnings.
• Increased interest expense on existing and future variable rate indebtedness.
• Changes in tax laws, examinations by tax authorities, and shifts in geographic income composition.
• Acquisition-related adverse effects, including integration difficulties, failure to achieve anticipated benefits, and regulatory approval issues.
• Compliance costs and potential liability related to U.S. and foreign data privacy and healthcare regulations (e.g., HIPAA, CCPA, GDPR), including data security breaches.
• Major disruptions in manufacturing, accounting, R&D, distribution facilities, or raw material supply chain due to integration challenges, disasters, or cybersecurity incidents.
• Failure of third-party vendors or technological problems, including information systems issues.
• Successful cybersecurity attacks leading to system disruptions or data loss.
• Market consolidation of large customers, leading to business concentration with fewer clients.
• Disruptions in supplies of raw materials, especially for silicone hydrogel lenses.
• New U.S. and foreign government laws and regulations, and changes in existing healthcare industry regulations (e.g., EU Medical Devices Regulation).
• Legal costs, insurance expenses, settlement costs, and adverse decisions from litigation (product liability, patent infringement, contractual disputes).
• Limitations on sales due to poor market acceptance of new products.
• New competitors, product innovations, or technologies.
• Reduced sales, customer loss, reputational harm, and costs from product recalls and warning letters.
• Failure or delays in receiving regulatory approvals or certifications for products.
• Failure of customers and end-users to obtain adequate coverage and reimbursement from third-party payers.
• Requirement to provide for significant liability or write off assets like goodwill and other intangibles.
• Success of R&D activities and other start-up projects.
• Dilution to earnings per share from acquisitions or stock issuance.
• Impact and costs from changes in accounting standards and policies.
• Risks related to environmental laws and requirements, including evolving regulations on hazardous substances.
• Risks related to environmental, social, and corporate governance (ESG) issues.
• The ongoing payroll tax dispute with HMRC, with a potential loss of up to $71.7 million plus interest, which could impact liquidity and cash flow if the appeal is unsuccessful.

Future Outlook

The company expresses optimism regarding the long-term prospects for the worldwide contact lens and general healthcare markets, anticipating continued resilience and growth for its businesses and products. However, it acknowledges significant risks and uncertainties in the global operating environment, including macroeconomic conditions, international conflicts, tariffs, foreign exchange rate fluctuations, regulatory developments, supply chain disruptions, and escalating global trade barriers.

Management Comments

• We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products.

Industry Context

StockSavvy.ai notes that The Cooper Companies' strong performance in both its CooperVision (contact lenses) and CooperSurgical (fertility and women's health) segments reflects robust demand in specialized healthcare markets. The growth in contact lenses, particularly in toric and multifocal categories and single-use silicone hydrogel products, aligns with broader industry trends favoring advanced lens technologies and convenient modalities. Similarly, the increase in fertility product sales within CooperSurgical indicates continued expansion in the assisted reproductive technology market. The company's focus on R&D in both segments positions it to capitalize on ongoing technological advancements and evolving patient needs, despite facing global macroeconomic and regulatory headwinds common across the medical device and pharmaceutical sectors.

Comparison to Industry Standards

• StockSavvy.ai notes that The Cooper Companies' 6.16% net sales growth and 26.9% diluted EPS increase for the quarter demonstrate strong operational execution, potentially outperforming some peers in the broader medical device and vision care sectors which may be experiencing more significant impacts from inflation or supply chain issues.
• CooperVision's 10% growth in toric and multifocal lenses, driven by products like MyDay and Biofinity, suggests effective product differentiation and market penetration in a competitive contact lens market, where innovation in materials and designs is key.
• CooperSurgical's 6% growth in fertility products indicates a healthy demand environment for specialized reproductive health solutions, a segment that often shows resilience due to its essential nature.
• The company's ability to reduce interest expense while maintaining a strong cash flow from operations suggests efficient capital management compared to industry averages, especially given the current interest rate environment.

Legal Proceedings

• The company is involved in a dispute with HM Revenue & Customs (HMRC) regarding payroll tax withholding matters related to the 2014 acquisition of the Sauflon Group.
• On March 2, 2026, the U.K. First-tier Tribunal (FTT) issued a decision that largely supports HMRC's position.
• The company believes the FTT's decision is incorrect and intends to appeal.
• An adverse outcome is reasonably possible, with an estimated loss ranging from $0 to $71.7 million, plus accrued interest.
• No liability reserves have been recorded as the company does not believe a loss is probable.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, EPS, and ongoing share repurchase program. Potential negative impact from the HMRC legal dispute if the appeal is unsuccessful, leading to a financial obligation.
• Employees: CooperSurgical saw a decrease in SGA expenses primarily due to a decrease in headcount, which could indicate workforce adjustments. Share-based compensation expenses increased, benefiting key employees.
• Customers: Continued focus on product innovation (e.g., MiSight 1 day lens, Biofinity Energys) and market penetration aims to benefit customers with advanced contact lens and healthcare solutions.
• Creditors: Improved operating cash flow and reduced interest expense, along with the extension of debt maturity for a significant portion of term loans, strengthen the company's ability to meet its debt obligations. Compliance with all debt covenants as of January 31, 2026.

Next Steps

• Appeal the U.K. First-tier Tribunal's decision regarding the HMRC payroll tax dispute.
• Continue evaluating the impact of new FASB accounting standards updates (ASU 2025-10, ASU 2025-07, ASU 2025-06, ASU 2025-05, ASU 2024-03, ASU 2023-09) on consolidated financial statements and disclosures.
• Adopt ASU 2023-09 for the fiscal year ending October 31, 2026.
• Expand manufacturing and research and development capacity through new leases commencing in the third quarter of fiscal 2026.
• Continue worldwide market penetration for CooperVision's recently introduced products and expand presence in existing and emerging markets.
• Focus on increasing demand for single-use silicone hydrogel products (clariti, MyDay, MyDay Energys) and FRP products (Biofinity, Avaira Vitality).
• Continue to enforce and defend patent and trademark rights for CooperSurgical products.

Key Dates

Recommendation

The Cooper Companies demonstrated robust financial performance in Q1 2026, with significant year-over-year growth in net sales, net income, and diluted EPS. Strong operating cash flow and effective debt management, including a substantial term loan maturity extension, enhance the company's financial stability. While the HMRC legal dispute presents a potential liability, the company's intent to appeal and the non-probable assessment of loss mitigate immediate concerns. The continued share repurchase program signals confidence in future value. The company's leadership in specialized healthcare markets (contact lenses, fertility, women's health) and ongoing R&D investments position it for sustained long-term growth, making it an attractive investment.

Keywords

contact lenses, women's health, fertility, medical devices, CooperVision, CooperSurgical, myopia management, silicone hydrogel, SEC filing, 10-Q, financial results, earnings, revenue growth, debt management, share repurchase, HMRC dispute, corporate governance, risk factors